Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
Clinical trial NCT07139470 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07139470
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-15
- Primary completion
- 2027-04-15
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.